Update shared on31 Aug 2025
Fair value Increased 2.16%The modest increase in Healthcare Realty Trust’s analyst price target reflects a slightly improved consensus revenue growth outlook, with fair value rising from $17.38 to $17.75.
What's in the News
- No share repurchases made in Q2 2025; total buyback to date is 3,679,162 shares (1.03%) for $63.04 million.
- Quarterly dividend approved at $0.24 per share and per operating partnership unit, applicable to relevant holders.
- 2025 earnings guidance lowered; expected loss per share now $0.78 to $0.73 vs. previous guidance of $0.28 to $0.20.
- Reported real estate asset impairments of $140.9 million in Q2 2025, up from $120.9 million year-over-year.
- Added to Russell 1000 Defensive Index and Russell 1000 Value-Defensive Index.
Valuation Changes
Summary of Valuation Changes for Healthcare Realty Trust
- The Consensus Analyst Price Target has risen slightly from $17.38 to $17.75.
- The Consensus Revenue Growth forecasts for Healthcare Realty Trust has significantly risen from -1.3% per annum to -1.1% per annum.
- The Net Profit Margin for Healthcare Realty Trust remained effectively unchanged, moving only marginally from 23.00% to 23.08%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.